HEALTH

J&J’s consumer group chair announces retirement

BY Michael Johnsen

NEW BRUNSWICK, N.J. Johnson & Johnson on Thursday reported that Colleen Goggins, worldwide chairman of the company’s consumer group, has announced her retirement from the company effective March 1, 2011.

“Throughout her tenure, Colleen has demonstrated our commitment to our consumers and our people, and has made major contributions to our success,” stated Bill Weldon, J&J chairman and CEO. “We thank Colleen for her dedication and extraordinary service, and wish her all the best in the years to come.”

Goggins joined Johnson & Johnson in 1981, and became president of J&J Canada in 1992; president of Personal Products Co., U.S. in 1994; and president of J&J Consumer in 1995. She was promoted to company group chairman in 1998. Goggins assumed her current position as a member of the executive committee in June 2001.

Weldon acknowledged that Goggins is among the group of executives that have led the effort to formulate and implement the remediation plan regarding the quality issues at McNeil. “In light of Colleen’s decision to retire, I am pleased that we have a clear remediation plan in place, and we will work together to ensure a smooth transition of her responsibilities,” Weldon said.

 

Both Weldon and Goggins recently were invited to testify on those quality issues for a Sept. 30 hearing hosted by the House of Representatives’ Committee on Oversight and Government Reform.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

House committee to hold hearing over J&J recall

BY Michael Johnsen

WASHINGTON House Committee on Oversight and Government Reform chairman Ed Towns, D-N.Y., on Thursday announced that the committee will hold a hearing Sept. 30 at 10 a.m. to examine the circumstances surrounding Johnson & Johnson’s recall of more than 135 million bottles of infant and children’s medicines produced by Johnson & Johnson/McNeil Consumer Healthcare, including children’s Tylenol, infant’s Tylenol, children’s Motrin and children’s Benadryl.

 

The hearing also will examine the circumstances surrounding a “phantom recall” of a particular Motrin product, which became public as a result of the committee’s hearing on May 27.

 

 

“This is about the safety of trusted medication that our children and grandchildren use,” Towns stated. “The evidence we have uncovered since our first hearing is extremely troubling.” 

 

 

Witnesses invited to testify include Bill Weldon, J&J chairman and CEO, and Colleen Goggins, J&J worldwide chairman, consumer group.

 

 

The hearing will be webcast on the committee’s website, Oversight.house.gov. 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Forest Pharmaceuticals pays $313 million in settlement deal

BY Alaric DeArment

SILVER SPRING, Md. Drug maker Forest Pharmaceuticals will pay more than $300 million to the federal government as part of a plea agreement over alleged improper drug distribution and obstructing a Food and Drug Administration inspection.

The FDA said Wednesday that Forest Pharmaceuticals, a subsidiary of New York-based Forest Labs, had entered a plea agreement whereby it would accept criminal responsibility for distribution of an unapproved drug, distribution of a misbranded drug and obstruction of an FDA inspection. The total payment of $313 million includes $164 million in criminal penalties.

One charge centered around the marketing of Levothroid (levothyroxine sodium), an unapproved drug used to treat hypothyroidism. A 1997 Federal Register notice announced that Levothroid is a “new drug,” and that manufacturers who wish to continue marketing it would have to obtain approval from the FDA by August 2000.

 

The company also is charged with alleged off-label promotion of the antidepressant Celexa (citalopram) for use in children; the drug is only approved for use in adults. The charge of obstructing an FDA inspection relates to an alleged 2003 incident in which Forest employees made false statements to the agency.

 

 

“We are pleased to bring closure to this long-running investigation,” Forest chairman and CEO Howard Solomon said. “We remain dedicated to ensuring that we operate in full compliance with all laws and regulations and that our employees uphold the highest principles of integrity, honesty and ethics.”

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?